SOC 2 Type II for Genomics Startups: What Auditors Actually Test
A SOC 2 report is supposed to prove something specific: that a company's security controls actually worked, day after day, for months, not just that they exist on paper. Most people assume that's what every SOC 2 report shows.
In March 2026, an anonymous whistleblower publishing under the name DeepDelver accused a Y Combinator-backed compliance automation startup, one that had raised $32 million at a $300 million valuation, of generating SOC 2 audit reports before any evidence was submitted. Analyzing a leaked spreadsheet of client audit files, the investigation found that 493 of 494 SOC 2 reports examined shared nearly identical boilerplate language, down to the same grammatical errors, with only the company name and logo changed (DeepDelver, "Delve - Fake Compliance as a Service - Part I," March 19, 2026). TechCrunch covered the story across several follow-up articles as investors began distancing themselves from the company.
For a genomics or precision medicine startup, this matters more than it might seem to at first. A SOC 2 report was never meant to prove a system is secure. It's meant to prove that specific, defined controls actually operated the way the company says they did, verified by an auditor who did the real work. A genomics startup that treats SOC 2 as a document to acquire, rather than a set of practices to build, usually finds that out at the worst possible moment: during due diligence with a hospital system or a health plan.
Key Takeaways
- SOC 2 is built on the AICPA's Trust Services Criteria: Security (mandatory for every report), plus Availability, Processing Integrity, Confidentiality, and Privacy, added based on what a company has actually committed to its customers (AICPA & CIMA)
- A Type II report differs from Type I in one critical way: Type I checks whether controls are designed correctly at a single point in time, while Type II verifies those controls actually operated correctly over an observation window, typically six to twelve months
- The observation window is the part that can't be shortcut. A control has to run for months to be tested for months; no automation platform can compress that timeline without skipping what the audit is actually for
- For a genomics platform, PHI and genomic data overlap directly with HIPAA obligations, which means the Security and Confidentiality criteria in a SOC 2 report and a lab's HIPAA technical safeguards end up covering much of the same ground, and gaps in one tend to show up in the other
What Does a SOC 2 Type II Report Actually Verify?
A SOC 2 report is an independent CPA firm's opinion on whether a company's controls, as described, are both designed appropriately and operating effectively against the AICPA's Trust Services Criteria. Security is mandatory in every report and covers access control, system operations, change management, and risk mitigation. The other four categories, Availability, Processing Integrity, Confidentiality, and Privacy, are scoped in based on what the company has actually promised its customers in contracts and service agreements, not chosen arbitrarily (AICPA & CIMA, 2017 Trust Services Criteria).
A precision medicine platform handling genomic and clinical data typically needs Security and Confidentiality at a minimum, since both genomic data and PHI carry re-identification risk that standard SaaS data doesn't. Availability often gets added if the platform is on the critical path for clinical reporting or turnaround time commitments. For a genomics startup building toward its first enterprise contract, this scoping decision, not the audit itself, is usually where the real preparation work starts.
What Is Actually Different About a Type II Audit Compared to a Type I?
Type I answers one question: are the controls designed correctly, evaluated at a single point in time? Type II answers a harder one: Did those controls actually operate correctly, consistently, over a period of months? An auditor pulls samples across the observation window, conducts monthly access reviews, performs quarterly vulnerability scans, reviews incident response logs, and checks whether the evidence matches what the company claims.
This is the part the 2026 compliance-automation controversy exposed. If an auditor's conclusions exist in a report before any evidence has been submitted, as the investigation into the Y Combinator-backed startup alleged, the observation window was never actually tested. A report can look identical to a real one and still describe controls that were never verified. That gap doesn't show up until an enterprise buyer, or an auditor doing a re-review, asks for the underlying evidence and finds nothing behind the PDF.
Why Does This Matter More for a Genomics Platform Than a Typical SaaS Company?
A generic SaaS company scoping SOC 2 usually starts and stops at Security. A genomics or precision medicine platform doesn't have that option because the data itself carries a different risk profile. Genomic data is immutable and identifies not just the patient but their biological relatives, and it sits alongside PHI under HIPAA; at the same time, it sits inside a SOC 2 Confidentiality scope. A control gap that would be a minor finding for a generic SaaS company, like inconsistent access logging, becomes a dual exposure here: a SOC 2 exception and a HIPAA technical safeguard failure in the same finding.
Labs and platforms operating under CLIA or CAP have an additional layer on top of that. Auditors reviewing access control and change management for a SOC 2 report are often looking at the same systems a CAP inspector will ask about during accreditation review, which means the evidence built for one can, and should, support the other. This is precisely where a genomics startup's compliance posture diverges from a general SaaS company's: the same access log has to satisfy three separate reviewers, not one.
Compliance Readiness
Not sure whether an existing architecture would hold up under this kind of dual scrutiny?
A 15-minute scoping call is enough to identify where SOC 2, HIPAA, and CAP/CLIA evidence requirements overlap in a specific system, and where they don't yet.
What Should a Startup Actually Prepare Before Starting the Observation Window?
The single most consequential decision is when to start the clock. The observation window can't be shortened once it begins, so starting it before access controls, logging, and change management are actually in place just means failing the audit on schedule instead of avoiding it. A readiness assessment before the window opens, checking whether MFA is enforced everywhere it's claimed, whether access reviews actually happen on the stated cadence, and whether incident response has ever been tested rather than just documented, is cheaper than finding the same gaps mid-audit.
For a genomics startup specifically, this readiness work overlaps directly with HIPAA technical safeguards and, where applicable, CLIA and CAP evidence requirements. Building the access control, audit logging, and PHI governance architecture once, so it satisfies SOC 2, HIPAA, and CAP/CLIA evidence requests from the same underlying system, is more defensible than building three separate compliance layers that drift apart from each other over time.
Audit trail evidence deserves its own attention here, because it's one of the most frequently requested and most frequently incomplete artifacts in a SOC 2 Type II review. NonStop's Varion accelerator is built specifically for 21 CFR Part 11-aligned audit trails, generating the time-stamped, tamper-evident change logs that both a SOC 2 auditor and an FDA-facing quality system expect to see, rather than a general application log retrofitted to look like one after the fact. For a genomics startup that will eventually need both SOC 2 evidence and Part 11-aligned records for any regulated workflow, building that audit trail architecture once is meaningfully cheaper than bolting it on twice.
Audit Trail Architecture
Curious what an audit-ready trail actually looks like before the observation window opens?
Seeing Varion run against a real workflow is the fastest way to know whether it fits.
NonStop has delivered software for regulated genomics and healthcare organizations under HIPAA, SOC 2, and GDPR requirements across more than 90 engagements since 2015, and the pattern holds consistently: the startups that treat compliance architecture as part of the system design, not a project bolted on before a fundraising round, are the ones whose Type II reports hold up when a health system's security team asks for the evidence behind them.
Frequently Asked Questions
How long does a SOC 2 Type II audit actually take for a genomics startup?
The observation window itself is typically six to twelve months, since Type II verifies operating effectiveness over time, not design at a single point. Readiness work before the window opens can shorten how much needs fixing mid-audit, but it can't shorten the window itself.
Can a startup skip Type I and go straight to Type II?
Yes, and many do once they have enough operating history to demonstrate controls over a real period. Type I is sometimes used as an earlier, faster proof point for a first enterprise deal, but it carries less weight than Type II with sophisticated buyers.
Does SOC 2 replace HIPAA compliance for a genomics platform?
No. SOC 2 is a voluntary attestation framework; HIPAA is a federal regulatory requirement. They overlap heavily in practice, since both require access control, audit logging, and breach response, but satisfying one doesn't automatically satisfy the other.
What evidence does a SOC 2 auditor typically pull for a genomics platform?
Beyond the standard access review logs, vulnerability scan results, and incident response records every SOC 2 Type II audit requires, a genomics or precision medicine platform should expect auditors to request evidence that ties directly to PHI handling: encryption key management records, Business Associate Agreement documentation for cloud and subprocessor vendors, and access logs that can isolate who touched genomic or clinical data specifically, not just who logged into the system generally (Censinet, SOC 2 Reporting FAQs for Healthcare Vendors). Auditors also increasingly expect a documented vendor inventory classifying which third parties can access PHI, since third-party risk is a recurring focal point in healthcare-adjacent SOC 2 reviews.
How does SOC 2 Type II affect a fundraising or enterprise sales process?
For a genomics startup selling into hospital systems, health plans, or other regulated buyers, a clean SOC 2 Type II report replaces a custom security questionnaire with a document the buyer's security team already knows how to evaluate, which is why it functions as a procurement gate for enterprise and healthcare buyers specifically. Without one, deals with security-conscious buyers can stall or be blocked outright during procurement. The same report increasingly shows up as a diligence item investors ask for directly, since a fabricated or thin report is now a known and searched-for red flag following the 2026 compliance-automation scandal.
A SOC 2 report only means something if the evidence behind it is real, and for a genomics platform handling PHI and genomic data at the same time, that evidence has to hold up under more than one kind of scrutiny.
Next Step
Talk to NonStop
If a startup is heading toward its first SOC 2 Type II engagement and isn't sure whether its architecture will hold up under real evidence testing, an AI Architecture Review is a 45-minute, no-pitch session that maps the gap between where the system is today and what a Type II audit will actually test.
References
- TechCrunch. "Delve accused of misleading customers with 'fake compliance.'" March 22, 2026.
- AICPA & CIMA. "2017 Trust Services Criteria (With Revised Points of Focus – 2022)."
- Censinet. "SOC 2 Reporting FAQs for Healthcare Vendors."
- ISpectra Technologies. "SOC 2 Compliance Hub: Framework, Audit, Type I & II Guide." 2026.
Mahendra works as a Sr. Bioinformatics Engineer at NonStop. He builds genomic pipelines, agentic AI systems, and AI-powered products for genomics and life sciences. He has 10+ years of experience in bioinformatics and genomics software. He studied Biotechnology at Mumbai University.